Moderna MRNA Stock Price, News & Analysis

The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. Moderna’s ‘next generation,’ Covid-19 vaccine has shown a higher immune response to the virus than the current version of the shot. Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine a… Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus’ arguments in a patent infringement lawsuit related to Moderna’s blockbuster COVID-19 vaccines. According to 16 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $132.58, which is an increase of 28.87% from the latest price.

Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Corinne Cardina has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. I think there are two things that explain what’s going on there. First of all, mutual funds and ETFs were probably already buying up shares of these stocks even before the announcement was made about their addition to the S&P 500.

Stéphane Bancel has an approval rating of 92% among the company’s employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances.

  1. They have an inkling of what’s going to happen before the announcement comes out, and so they go ahead and start making some buys.
  2. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics.
  3. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
  4. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
  5. Elis closes the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 26 February 2024 – Elis, the global leader in circular services at work, today announces the acquisition of 100% of Mo…

Put very simply, a vaccine utilizing mRNA technology teaches the body to make its own medicine. This is different than traditional vaccines where a harmless version of a virus or bacteria is used to trigger an immune response. Moderna had been working on this technology for nearly a decade before the pandemic broke out, putting the company in a position to get a vaccine to market very quickly. For investors who make Moderna a reasonably sized part of a diversified portfolio, I think the stock is a buy today. As Moderna brings more products to the market, there will be additional opportunities to add to the position over time. MRNA, +4.70% rose 1.1% in premarket trading Tuesday, after the biotechnology company said its next-generation COVID-19 vaccine produced positive results in a late-stage trial.

The consensus among Wall Street equities research analysts is that investors should “hold” MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares. As of this writing, the only commercially available product Moderna has is its COVID-19 vaccine. While this revenue stream has slowed drastically, it should continue into the foreseeable future. The company will develop updated versions as the virus continues to change over time.

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter. Moderna’s Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs. The vaccine maker announces that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program. All market data (will open in new tab) is provided by Barchart Solutions.

Company Profile

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, hotforex broker intratumoral immuno-oncology and systemic intracellular therapeutics. 16 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Moderna in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 5 buy ratings for the stock.

MRNA-Q Related ETFs

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company’s weighted average against that of other companies. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work interactive brokers forex review and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. The stellar efficacy and safety profile of Moderna’s COVID-19 vaccine offered rapid validation of the firm’s mRNA technology.

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

They have an inkling of what’s going to happen before the announcement comes out, and so they go ahead and start making some buys. I was curious to see how the stocks that have been added so far this year to the S&P 500 have performed. The company is scheduled to release power trend its next quarterly earnings announcement on Thursday, May 2nd 2024. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna’s new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu. Moderna CEO Stephane Bancel joins ‘Squawk Box’ to discuss the company’s annual vaccines day, the announcement of multiple vaccine programs advancing to late-stage clinical trials, Moderna’s vaccines p… Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-ov… They just revealed what they believe are the ten best stocks for investors to buy right now… That’s right — they think these 10 stocks are even better buys. 57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com.

The 10 stocks that made the cut could produce monster returns in the coming years. The launch of the RSV vaccine is already being planned for by the company, which believes there is a $10 billion global market for this drug. In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market. Moderna (MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Moderna. Elis closes the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 26 February 2024 – Elis, the global leader in circular services at work, today announces the acquisition of 100% of Mo… Moderna Inc. (MRNA) on Tuesday reported “positive interim results” from a late-stage study of what it calls the “next-generation COVID-19 vaccine.” “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.

What is important for the future of the business, and for current and potential investors, is the pipeline of future products. Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Leave a Comment

Your email address will not be published. Required fields are marked *